ConductScience.org, home

Disease · HP_0001601

Laryngomalacia

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. Laryngomalacia. Diseases, record HP_0001601. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001601

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
Laryngomalacia
Open Targets ID
HP_0001601
Other names
Softening of voice box tissue
Highest stage of its drugs
Phase 1/2, for 1 of its 3 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
FAMOTIDINECHEMBL902Small moleculePhase 1/2ClinicalTrials.gov222Drugs and targets
OMEPRAZOLECHEMBL1503Small moleculePhase 1ClinicalTrials.gov111Drugs and targets
RANITIDINECHEMBL1790041Small moleculeUnknownClinicalTrials.gov111Drugs and targets

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
HRH2Histamine H2 receptor2Histamine H2 receptor antagonistPhase 1/2https://conductscience.org/library/genes/3274Drugs and targets
ATP4APotassium-transporting ATPase1Potassium-transporting ATPase inhibitorPhase 1https://conductscience.org/library/genes/495Drugs and targets
ATP4BPotassium-transporting ATPase1Potassium-transporting ATPase inhibitorPhase 1https://conductscience.org/library/genes/496Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT04614974Initiation of Acid Suppression Therapy Prospective Outcomes for LaryngomalaciaPhase 1/2652025-07-20Laryngomalacia, Gastro Esophageal RefluxFAMOTIDINEIts record names the diseaseClinicalTrials.gov
NCT01782560Laryngomalacia StudyPhase 10LaryngomalaciaOMEPRAZOLEIts record names the diseaseClinicalTrials.gov
NCT02700087In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?Not applicable0Laryngomalacia, Acid Reflux, StridorFAMOTIDINE, RANITIDINEIts record names the diseaseClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Speech Language Therapy Alone vs Speech Language Therapy and Acid Suppression Therapy: Number of Participants With the Need for Supraglottoplasty Surgery (Escalation of Treatment) up to 1 Year2 of 341 of 3165NCT04614974Trial comparisons
Speech Language Therapy Alone vs Speech Language Therapy and Acid Suppression Therapy: deaths from any cause0 of 340 of 3165NCT04614974Trial comparisons
Speech Language Therapy Alone vs Speech Language Therapy and Acid Suppression Therapy: Number of Participants With the Need for a Different Acid Suppression Therapy Medication (Other Than Famotidine) From the Day After the Consult up to the 3 Month Follow up Appointment
0 of 342 of 3165NCT04614974Trial comparisons
Speech Language Therapy Alone vs Speech Language Therapy and Acid Suppression Therapy: serious adverse events3 of 343 of 3165NCT04614974Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing it
40762274DERIVED1

Source PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001601

GET https://conductscience.org/api/diseases/v1/HP_0001601/drugs